These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 28538979)

  • 1. Stanniocalcin-1 Is an Ocular Hypotensive Agent and a Downstream Effector Molecule That Is Necessary for the Intraocular Pressure-Lowering Effects of Latanoprost.
    Roddy GW; Viker KB; Winkler NS; Bahler CK; Holman BH; Sheikh-Hamad D; Roy Chowdhury U; Stamer WD; Fautsch MP
    Invest Ophthalmol Vis Sci; 2017 May; 58(5):2715-2724. PubMed ID: 28538979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stanniocalcin-1 (STC-1), a downstream effector molecule in latanoprost signaling, acts independent of the FP receptor for intraocular pressure reduction.
    Roddy GW; Rinkoski TA; Monson KJ; Chowdhury UR; Fautsch MP
    PLoS One; 2020; 15(5):e0232591. PubMed ID: 32365129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of prostaglandin analogues on IOP in prostanoid FP-receptor-deficient mice.
    Ota T; Aihara M; Narumiya S; Araie M
    Invest Ophthalmol Vis Sci; 2005 Nov; 46(11):4159-63. PubMed ID: 16249494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stanniocalcin-1 Reduced Intraocular Pressure in Two Models of Ocular Hypertension.
    Roddy GW; Chowdhury UR; Monson KJ; Fautsch MP
    Curr Eye Res; 2021 Oct; 46(10):1525-1530. PubMed ID: 33757401
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of Cromakalim Prodrug 1 (CKLP1) on Aqueous Humor Dynamics and Feasibility of Combination Therapy With Existing Ocular Hypotensive Agents.
    Roy Chowdhury U; Rinkoski TA; Bahler CK; Millar JC; Bertrand JA; Holman BH; Sherwood JM; Overby DR; Stoltz KL; Dosa PI; Fautsch MP
    Invest Ophthalmol Vis Sci; 2017 Nov; 58(13):5731-5742. PubMed ID: 29114841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostaglandin analogues and mouse intraocular pressure: effects of tafluprost, latanoprost, travoprost, and unoprostone, considering 24-hour variation.
    Ota T; Murata H; Sugimoto E; Aihara M; Araie M
    Invest Ophthalmol Vis Sci; 2005 Jun; 46(6):2006-11. PubMed ID: 15914616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Latanoprost and Bimatoprost on the Expression of Molecules Relevant to Ocular Inflow and Outflow Pathways.
    Li X; He F; Gabelt BT; Wang Y; Cai S; Cao J; Fan N; Kaufman PL; Liu X
    PLoS One; 2016; 11(3):e0151644. PubMed ID: 27011234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subconjunctival Administration of an Adeno-Associated Virus Expressing Stanniocalcin-1 Provides Sustained Intraocular Pressure Reduction in Mice.
    Roddy GW; Kohli D; Niknam P; Omer ME; Chowdhury UR; Anderson KJ; Pacheco Marrero JM; Rinkoski TA; Fautsch MP
    Ophthalmol Sci; 2025; 5(1):100590. PubMed ID: 39328825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased intraocular pressure in mice following either pharmacological or genetic inhibition of ROCK.
    Whitlock NA; Harrison B; Mixon T; Yu XQ; Wilson A; Gerhardt B; Eberhart DE; Abuin A; Rice DS
    J Ocul Pharmacol Ther; 2009 Jun; 25(3):187-94. PubMed ID: 19456252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2α agonist, in preclinical models.
    Krauss AH; Impagnatiello F; Toris CB; Gale DC; Prasanna G; Borghi V; Chiroli V; Chong WK; Carreiro ST; Ongini E
    Exp Eye Res; 2011 Sep; 93(3):250-5. PubMed ID: 21396362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of latanoprost on intraocular pressure in mice lacking the prostaglandin FP receptor.
    Crowston JG; Lindsey JD; Aihara M; Weinreb RN
    Invest Ophthalmol Vis Sci; 2004 Oct; 45(10):3555-9. PubMed ID: 15452062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Latanoprost-Eluting Contact Lenses in Glaucomatous Monkeys.
    Ciolino JB; Ross AE; Tulsan R; Watts AC; Wang RF; Zurakowski D; Serle JB; Kohane DS
    Ophthalmology; 2016 Oct; 123(10):2085-92. PubMed ID: 27586444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ocular Hypotensive Effects of the ATP-Sensitive Potassium Channel Opener Cromakalim in Human and Murine Experimental Model Systems.
    Roy Chowdhury U; Bahler CK; Holman BH; Dosa PI; Fautsch MP
    PLoS One; 2015; 10(11):e0141783. PubMed ID: 26535899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover study.
    Lim KS; Nau CB; O'Byrne MM; Hodge DO; Toris CB; McLaren JW; Johnson DH
    Ophthalmology; 2008 May; 115(5):790-795.e4. PubMed ID: 18452763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of prostaglandin F2alpha and latanoprost on phosphoinositide turnover, myosin light chain phosphorylation and contraction in cat iris sphincter.
    Ansari HR; Davis AM; Kaddour-Djebbar I; Abdel-Latif AA
    J Ocul Pharmacol Ther; 2003 Jun; 19(3):217-31. PubMed ID: 12828840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparative study of latanoprost (Xalatan) and isopropyl unoprostone (Rescula) in normal and glaucomatous monkey eyes.
    Serle JB; Podos SM; Kitazawa Y; Wang RF
    Jpn J Ophthalmol; 1998; 42(2):95-100. PubMed ID: 9587840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of topical hypotensive drugs on circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure in patients with glaucoma.
    Quaranta L; Gandolfo F; Turano R; Rovida F; Pizzolante T; Musig A; Gandolfo E
    Invest Ophthalmol Vis Sci; 2006 Jul; 47(7):2917-23. PubMed ID: 16799034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A dual acting compound with latanoprost amide and nitric oxide releasing properties, shows ocular hypotensive effects in rabbits and dogs.
    Impagnatiello F; Borghi V; Gale DC; Batugo M; Guzzetta M; Brambilla S; Carreiro ST; Chong WK; Prasanna G; Chiroli V; Ongini E; Krauss AH
    Exp Eye Res; 2011 Sep; 93(3):243-9. PubMed ID: 21356209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of latanoprost on rodent intraocular pressure.
    Husain S; Whitlock NA; Rice DS; Crosson CE
    Exp Eye Res; 2006 Dec; 83(6):1453-8. PubMed ID: 17027754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the diurnal ocular hypotensive efficacy of travoprost and latanoprost over a 44-hour period in patients with elevated intraocular pressure.
    Dubiner HB; Sircy MD; Landry T; Bergamini MV; Silver LH; Darell Turner F; Robertson S; Andrew RM; Weiner A; Przydryga J
    Clin Ther; 2004 Jan; 26(1):84-91. PubMed ID: 14996520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.